A new statistical analysis of patients with follicular lymphoma, made possible by 15 years of follow-up data from a SWOG and ...

NICE recommends epcoritamab for relapsed follicular lymphoma, offering a new option after multiple lines of therapy.

Please provide your email address to receive an email when new articles are posted on . Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has ...

Follicular lymphoma is a slow-growing cancer that spreads through a person’s lymphatic system. Doctors may treat follicular lymphoma as they would a chronic condition, and the outlook is generally ...

Mantle-cell lymphoma accounts for approximately 5 to 7% of all lymphomas, and in North America and Europe, the frequency is similar to that of noncutaneous, peripheral T-cell lymphomas. The median age ...

How many collision tumors have you seen among your patients? While relatively rare, these neoplasms—which co-exist at the same anatomical site and yet are histologically distinct—do occur. 1 The ...

Patients with a history of cutaneous melanoma are at increased risk of developing lymphoid neoplasms and vice versa. This study found that these risks differ by subtype of lymphoid neoplasm and that ...

Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows ...